Inside Q2's AI Drug Discovery Mega-Rounds
AI drug discovery and SMR funding are consolidating around fewer, larger bets as broader digital health deal volume hits a decade low.
AI drug discovery and SMR funding are consolidating around fewer, larger bets as broader digital health deal volume hits a decade low.
Digital health deal count fell 36% quarter-over-quarter in Q2 2026, yet funding concentrated in outsized AI drug discovery rounds—Isomorphic Laboratories alone claimed over a third of the sector's quarterly total. Meanwhile, small modular reactor investment is tracking toward $1.7B this year, fueled by data-center power demand. Humanoid robotics adds another signal: Bosch and Schaeffler invested in Humanoid *and* became customers, suggesting equity-plus-deployment commitments may define which robotics plays reach commercial scale first.
Watch: Whether customer-led equity rounds in humanoid robotics become the new diligence benchmark, crowding out purely financial backers.
Below, we break down some of tech’s biggest stories, with analyst perspective on the moves that matter the most. Here’s what we’re watching this week: AI drug discovery mega-rounds AI 100 winner Humanoid reaches unicorn status Fresh nuclear funding This brief is adapted from our weekly newsletter. Sign up here to get it in your inbox every Thursday. 1. AI drug discovery companies scored Q2’s largest digital health deals. Digital health deal activity fell 36% QoQ in Q2’26, its fewest quarterly deals in more than a decade. Funding also declined, down 24% to $5.7B, as investors put more money into fewer, larger rounds centered on AI drug discovery, including the top 2 rounds this quarter: Isomorphic Laboratories ($2.1B Series B, more than a third of digital health’s total quarterly funding) Chai Discovery ($400M Series C at a $3.8B valuation) Get the full quarterly breakdown in CB Insights’ State of Digital Health Q2’26 report. 2. Humanoid reaches unicorn status, confirming our AI 100 call. Humanoid , a European wheeled humanoid developer, raised a $152M Series A round at a $1.35B valuation, joining 20+ other humanoid unicorns . The round is the most recent to shine a spotlight on the broader humanoid robotics market, where industrial customers are increasingly writing equity checks alongside commercial deployments. We named Humanoid to the AI 100 earlier this year, on the strength of its wheeled robot platform and early industrial partnerships. Schaeffler and Bosch invested and are also customers. Bosch is serving as a contract manufacturer, while Schaeffler committed to purchase thousands of wheeled units through 2032. But the round is about more than one deal. A customer writing an equity check alongside a pilot is a stronger signal of commercial traction than funding size alone, potentially reshaping which humanoid bets make it first to commercial scale. Check out our AI 100 report to see the rest of the winners. 3. AI power demand is turning small nuclear reactors into a big funding category. Data centers are pushing power demand past what the grid can supply. Investors are betting on small modular reactors to meet the shortfall. Antares Nuclear raised a $470M Series C this week to build small reactors for military bases, one of three DOE pilot winners turning a recent milestone into funding. Other SMR developers are raising alongside it: Valar Atomics is in talks to raise $1B at a $6B valuation after delivering power from its reactor to an NVIDIA AI chip cluster. Blue Energy raised $380M, then landed a strategic investment from Constellation Energy, its first in an SMR company. Aalo Atomics raised a $100M Series B for a reactor built for AI data centers. Funding is on pace for $1.7B this year, the second highest total ever, following a record $2.4B in 2025. Most of these reactors are not expected to run at scale until the early 2030s. See the full set of SMR deal activity this year on the CB Insights deals search . More CB Insights Research: State of Digital Health Q2’26 Report State of AI Q2’26 Report The State of Venture Tracker The post Inside Q2’s AI drug discovery mega-rounds appeared first on CB Insights Research .
- 01Digital health deal count fell 36% quarter-over-quarter in Q2 2026, yet funding concentrated in outsized AI drug discovery rounds—Isomorphic Laboratories alone claimed over a third of the sector's quarterly total.
- 02Meanwhile, small modular reactor investment is tracking toward $1.7B this year, fueled by data-center power demand.
- 03Humanoid robotics adds another signal: Bosch and Schaeffler invested in Humanoid *and* became customers, suggesting equity-plus-deployment commitments may define which robotics plays reach commercial scale first.